Western Asset Municipal Defined Opportunity Trust Inc. (NYSE: MTT) Announces Completed Termination

Western Asset Municipal Defined Opportunity Trust Inc. (NYSE: MTT) Announces Completed Termination

NEW YORK–(BUSINESS WIRE)–
Western Asset Municipal Defined Opportunity Trust Inc. (the “Fund”) announced today that the Fund terminated as scheduled on April 30, 2021. The proportionate interests of stockholders in the assets of the Fund were determined as of that date. The Fund’s liquidating distribution of $21.1993 per share is anticipated to be paid on or about May 5, 2021. Prior to the opening of business on May 3, 2021, the Fund ceased trading on the New York Stock Exchange.

The Fund, a non-diversified, closed-end management investment company, is managed by Legg Mason Partners Fund Advisor, LLC (“LMPFA”) and is sub-advised by Western Asset Management Company, LLC (“Western Asset”), an affiliate of LMPFA. Both LMPFA and Western Asset are indirect, wholly-owned subsidiaries of Franklin Resources, Inc. (“Franklin Resources”).

The Fund files its semi-annual and annual reports with the Securities and Exchange Commission (the “SEC”). These reports are available on the SEC’s website at www.sec.gov. Contact the Fund at 1-888-777-0102 for additional information, or consult the Fund’s web site at www.lmcef.com. Hard copies of the Fund’s complete audited financial statements are available free of charge upon request.

Data and commentary provided in this press release are for informational purposes only. This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the Fund’s current plans and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning such risks and uncertainties are contained in the Fund’s filings with the SEC. Franklin Resources and its affiliates do not engage in selling shares of the Fund.

Category: Fund Announcement

Source: Franklin Resources, Inc.

Source: Legg Mason Closed End Funds

Fund Investor Services-1-888-777-0102

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Newmont Celebrates 100 Years

Newmont Celebrates 100 Years

Company celebrates milestone while looking toward a bright future

DENVER–(BUSINESS WIRE)–
This week, Newmont Corporation (NYSE: NEM, TSX:NGT) honors Colonel William Boyce Thompson’s spirit of exploration on the 100th year since the Company’s founding in 1921.

From its early beginnings in mining in California, Newmont grew to become a geographically diverse and diversified mining house headquartered in New York, N.Y. The Company returned its focus to gold in the 1960s with the discovery of Nevada’s prolific Carlin Trend. Following international expansion and series of transformational mergers and acquisitions, today, Newmont is the world’s leading gold mining company with 12 operating mines and two joint ventures, all in top-tier jurisdictions.

“It’s an honor to lead Newmont Corporation at such a pivotal time in our history. This milestone offers us a clear moment in time to celebrate our achievements and reflect as we move into the next 100 years of mining,” stated Tom Palmer, President and Chief Executive Officer of Newmont. “Throughout our history, Newmont has been a catalyst for change. With a vibrant history, we have transformed; embracing new jurisdictions and innovative technologies. None of this would have been possible without our people, who have consistently risen to the challenge. I am excited about the strength and stability of our portfolio, the capabilities of our workforce and the opportunities we have in front of us.”

A truly global company with more than 14,000 employees around the world at its 12 operating mines, Newmont’s organic pipeline is the best in the industry, all underpinned by the Company’s clear strategic focus, proven operating model and superior execution. Recognized for its commitment to health and safety, Newmont is an industry leader in environmental, social and governance (ESG) practices. The Company continues to spur change with its climate change targets to reduce carbon emissions by 30% by 2030 and aspirations to be net carbon zero by 2050. With these targets and its culture of superior operational and project execution and focus on delivering sustainable shareholder returns, Newmont looks forward to continuing to deliver on its purpose to create value and improve lives through sustainable and responsible mining.

About Newmont

Newmont is the world’s leading gold company and a producer of copper, silver, zinc and lead. The Company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in North America, South America, Australia and Africa. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social and governance practices. The Company is an industry leader in value creation, supported by robust safety standards, superior execution and technical expertise. Newmont was founded in 1921 and has been publicly traded since 1925.

To learn more about Newmont, visit www.newmont.com.

Media Contact

Courtney Boone

303.837.5159

[email protected]

Investor Contact

Eric Colby

303.837.5724

[email protected]

KEYWORDS: Colorado United States North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo

Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021

Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021

Conference Call Scheduled for Monday, May 10, 2021 at 4:30 p.m. ET.

NASHVILLE, Tenn.–(BUSINESS WIRE)–
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release first quarter 2021 financial results on Monday, May 10, 2021 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 5082423; or from the webcast link in the investor relations section of the company’s website at: www.revance.com.

A replay of the call will be available beginning May 10, 2021 at 4:30 p.m. PT / 7:30 p.m. ET to May 11, 2021 at 4:30 p.m. PT / 7:30 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference ID: 5082423. The webcast will be available in the investor relations section on the company’s website for 30 days following the completion of the call.

In light of reduced call center resources during this time of required social-distancing, Revance requests listeners not planning on participating in Q&A to listen to the live webcast rather than dialing in by phone.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications – cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 626-589-1007

[email protected]

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

[email protected]

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

[email protected]

or

General Media:

Goodfuse:

Jenifer Slaw, 347-971-0906

[email protected]

or

Trade Media:

Nadine Tosk, 504-453-8344

[email protected]

KEYWORDS: Tennessee United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Mednow to Host Webcast on May 4, 2021

Mednow to Host Webcast on May 4, 2021

TORONTO–(BUSINESS WIRE)–
Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW), Canada’s on-demand virtual pharmacy, is pleased to announce the Company will be hosting a webcast investor presentation on Tuesday, May 4, 2021 at 1pm ET.

During the webcast, Karim Nassar, Chief Executive Officer, and Ali Reyhany, President, will provide a business update on Mednow’s national expansion and recent strategic milestones.

Webcast details:

Link:

 

https://us02web.zoom.us/j/83205777592?pwd=UEpGV3FsZS9tUGZ0RkRwTDE0YWRnQT09

Zoom ID:

 

832 0577 7592

Passcode:

 

372831

About Mednow Inc.

Mednow is a healthcare technology company offering virtual access with exceptional care. Designed with access and quality care in mind, Mednow.ca provides virtual pharmacy services with convenience and through an interdisciplinary approach to healthcare that is focused on the patient experience. Pharmacy services include free at-home delivery of medications, a user-friendly interface for easy upload, transfer and refill of prescriptions, access to healthcare professionals through an intuitive chat experience, a specialized PillSmart™ system that packages prescriptions and vitamins by date and time, as well as access to telemedicine.

To learn more, follow Mednow on Facebook, Twitter, LinkedIn and Instagram, as well as visit www.mednow.ca/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investor Relations Contact:

Marc Charbin

[email protected]

1.855.686.6300

Media Contact:

Jalila Singerff

Jive PR + Digital

www.jiveprdigital.com

[email protected]

613.614.6777

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Technology Software Practice Management Internet Managed Care Health Pharmaceutical General Health Data Management

MEDIA:

Logo
Logo

Colony Credit Real Estate Announces Completion of Internalization

Colony Credit Real Estate Announces Completion of Internalization

NEW YORK–(BUSINESS WIRE)–
Colony Credit Real Estate, Inc. (NYSE: CLNC) (the “Company”) today announced the completion of the previously announced internalization of the Company’s management and operating functions and termination of the management agreement between the Company and its external manager, CLNC Manager, LLC, a subsidiary of Colony Capital, Inc. (the “Manager” or “Colony Capital”). The Company made a one-time cash payment of $102.3 million to the Manager to terminate the management agreement.

The internalization will enhance the Company’s positioning and is expected to produce meaningful benefits to all stockholders, including:

  • substantial anticipated cost savings of approximately $14 to 16 million per year, or approximately $0.10 to 0.12 per share of common stock;
  • management continuity and team expertise, led by Michael J. Mazzei, Chief Executive Officer & President, Andrew Witt, Chief Operating Officer, Frank V. Saracino, Chief Financial Officer & Chief Accounting Officer, David A. Palamé, General Counsel & Secretary, and approximately 45 employees who have contributed substantially to the Company’s investment, portfolio management, servicing, financial reporting and related operations;
  • further alignment of management with the Company and stockholders, with an internalized structure, more transparent organizational model and dedicated employee base focused solely on the Company; and
  • rebranding to reflect the Company’s evolution, which rebranding as a self-managed Company is an important milestone and anticipated in the coming months.

Additional details regarding the internalization and related matters will be contained in a Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission on May 3, 2021.

About Colony Credit Real Estate, Inc.

Colony Credit Real Estate (NYSE: CLNC) is one of the largest publicly traded commercial real estate (CRE) credit REITs, focused on originating, acquiring, financing and managing a diversified portfolio consisting primarily of CRE debt investments and net leased properties predominantly in the United States. CRE debt investments primarily consist of first mortgage loans, which we expect to be the primary investment strategy. Colony Credit Real Estate is organized as a Maryland corporation and taxed as a REIT for U.S. federal income tax purposes. For additional information regarding the Company and its management and business, please refer to www.clncredit.com.

Cautionary Statement Regarding Forward-Looking Statements.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and contingencies, many of which are beyond our control, and may cause actual results to differ significantly from those expressed in any forward-looking statement. Among others, the following uncertainties and other factors could cause actual results to differ from those set forth in the forward-looking statements: operating costs and business disruption from the internalization transaction may be greater than expected, which could reduce the potential cost savings anticipated in the internalization transaction; uncertainties regarding the ongoing impact of the novel coronavirus (COVID-19); the ability to realize efficiencies as well as anticipated strategic and financial benefits of the internalization; whether the Company will achieve its anticipated 2021 Distributable Earnings per share (as adjusted), or maintain or produce higher Distributable Earnings per share (as adjusted) in the near term or ever; the possibility that the Company may not be able to retain key employees; and the Company’s ability to maintain or grow the dividend at all in the future. The foregoing list of factors is not exhaustive. Additional information about these and other factors can be found in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as in Colony Credit Real Estate’s other filings with the U.S. Securities and Exchange Commission. Moreover, each of the factors referenced above are likely to also be impacted directly or indirectly by the ongoing impact of COVID-19 and investors are cautioned to interpret substantially all of such statements and risks as being heightened as a result of the ongoing impact of the COVID-19.

We caution investors not to unduly rely on any forward-looking statements. The forward-looking statements speak only as of the date of this press release. Colony Credit Real Estate is under no duty to update any of these forward-looking statements after the date of this press release, nor to conform prior statements to actual results or revised expectations, and Colony Credit Real Estate does not intend to do so.

Investor Relations

Colony Credit Real Estate, Inc.

Addo Investor Relations

Lasse Glassen

310-829-5400

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Construction & Property Professional Services REIT Finance

MEDIA:

Logo
Logo

The Parent Company Announces Participation in Upcoming Conferences

The Parent Company Announces Participation in Upcoming Conferences

SAN JOSE, Calif.–(BUSINESS WIRE)–TPCO Holding Corp. (“The Parent Company”) (NEO: GRAM.U, GRAM.WT.U) (OTCQX: GRAMF; OTC PINK: GRMWF), today announced that Steve Allan, Chief Executive Officer, will participate in the following upcoming conferences:

  • Eight Capital “Seed to Scale: Emerging Opportunities in US Cannabis” Virtual Conference, being held on Tuesday, May 4, 2021. Management is scheduled to virtually present at 1:50 p.m. ET.
  • Canaccord Genuity Cannabis Virtual Conference, being held on Tuesday, May 11, 2021. Management is scheduled to virtually present at 10:30 a.m. ET. A webcast recording of the event will be available in the Investor Relations section of the Company’s website.

About The Parent Company:

The Parent Company (TPCO Holding Corp.) (NEO: GRAM.U, GRAM.WT.U) (OTCQX: GRAMF; OTC PINK: GRMWF) is California’s leading vertically integrated cannabis company combining best-in-class operations with leading voices in popular culture and social impact. The Parent Company brings together global icon and entrepreneur Shawn “JAY-Z” Carter, entertainment powerhouse ROC NATION, California’s leading direct-to-consumer platform CALIVA, and leading cannabis and hemp manufacturer, LEFT COAST VENTURES, to form a cannabis industry leader for the post-prohibition era. Chief Visionary Officer Shawn “JAY-Z” Carter, one of the most recognized and celebrated entrepreneurs of our time, will guide The Parent Company’s brand strategy in partnership with Roc Nation, the world’s preeminent entertainment company with a roster of culture-making artists, athletes and influencers. The brands we build together will pave a new path forward for a legacy rooted in equity, access, and justice.

For the latest news, activities, and media coverage, please visit www.theparent.co or connect with us on LinkedIn and Twitter.

Investor Contact:

Rob Kelly

MATTIO Communications

[email protected]

Media Contact:

Nike Communications

[email protected]

KEYWORDS: United States North America Canada California

INDUSTRY KEYWORDS: Other Health Entertainment General Health Pharmaceutical Other Natural Resources Natural Resources General Entertainment Other Entertainment Celebrity Music Alternative Medicine Health

MEDIA:

Logo
Logo

Nanox Announces Appointment of Medical Executive Moshe Shtengel as Chief Business Officer

Appointment adds to the Nanox team extensive experience in global medical business development and sales

NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) — NANOX IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products.

“Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field,” stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. “As we ramp up our manufacturing capabilities in preparation for the commencement of commercial shipments to our service partners, Moshe’s experience will prove invaluable as we strive to execute an efficient and seamless launch of our novel technology.”

“Throughout my career, I have had the pleasure of participating in the launch and commercialization of revolutionary technologies that represent a significant technological leap forward in their field,” stated Mr. Shtengel. “The Nanox.ARC, the company’s novel digital x-ray source technology, is consistent with that theme. With the recent FDA clearance of the Nanox Cart X-Ray System and potential clearance of the multi-source system for commercial use, I am delighted and privileged to join the company and contribute to a successful launch plan that maximizes the reach of this potentially life-saving technology. I look forward to achieve the company’s goal of democratizing medical imaging globally.”

Prior to Tuttnauer, Mr. Shtengel served as EMEA Health of Sales and Marketing, Surgical Business Unit at Lumenis Ltd., a global leader in the field of minimally invasive clinical solutions for the surgical, ophthalmology and aesthetic markets. Prior to that, he served as Head of Global Sales and Marketing at Truphatek International Ltd., a leading global medical device company. Before that, Mr. Shtengel was Head of Clinical Trial and Compliance Business Unit at BJC Healthcare, one of the largest health care organizations in the United States.

Mr. Shtengel earned his BA in Economics in Business Administration from Ben Gurion University of Negev, Israel and his Master of Business Administration (MBA) with majors in Marketing and General Management from the Fuqua School of Business, Duke University.

About Nanox:

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and Nanox’s ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox’s expectations.

Contacts:

Investors

Itzhak Maayan
Nanox Imaging
[email protected]

Bob Yedid
LifeSci Advisors
646-597-6989
[email protected]

Media

Alona Stein
ReBlonde for Nanox   
[email protected]



PolarityTE to Report First Quarter Financial Results on May 13, 2021

PolarityTE to Report First Quarter Financial Results on May 13, 2021

SALT LAKE CITY–(BUSINESS WIRE)–PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximately 4:00 p.m. Eastern Time.

In addition, the Company will host a conference call and webcast with Q&A on May 13, 2021 at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing 1-800-377-1217 (U.S. and Canada) or +44 (0)330 027 2386 (International) with confirmation code 231666 and referencing “PolarityTE First Quarter 2021 Earnings Call”. A webcast of the conference call can be accessed by using the link below.

Earnings Call Webcast – CLICK HERE

A replay of the earnings conference call will be available for 30 days, beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE’s website at https://www.polarityte.com/news-media/events, or by clicking on the link above.

About PolarityTE®

PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient’s own tissue and uses the patient’s own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE’s innovative methods are intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.

Forward Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to the impact of the COVID-19 pandemic and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

Investors:

Rich Haerle

VP, Investor Relations

PolarityTE, Inc.

[email protected]

(385) 315-0697

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Biotechnology General Health Other Health Health Medical Supplies

MEDIA:

Logo
Logo

IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–
IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.

“This is an exciting milestone for Corium as we prepare to bring AZSTARYS to market and provide patients with ADHD and their clinicians a new option for rapid and extended symptom control,” said Perry J. Sternberg, President and CEO of Corium. “To successfully do this, we need a partner with the expertise, resources, and technology to help us efficiently engage with clinicians and connect the right patients to this treatment. We are thrilled to be partnering with IQVIA to support and execute our commercialization strategy for AZSTARYS.”

Under the agreement, IQVIA will deploy a tailored combination of technology, analytics, and field services to enable coordinated, effective engagements with healthcare professionals who treat ADHD. IQVIA’s team of sales reps and medical liaisons will complement Corium’s deep internal ADHD and commercialization expertise and customer-facing leadership. Corium will also be supported by IQVIA’s Orchestrated Customer Engagement (OCE) SaaS-based platform, which connects sales, marketing, and medical with AI-enabled recommendations through an intuitive and efficient user experience.

“This is an excellent example of how IQVIA’s depth of expertise and breadth of offerings can support companies that are launching for the first time and need to maximize every engagement,” said Susan Kitlas, a vice president of sales dedicated to pre-commercial clients. “Leveraging IQVIA Connected Intelligence, Corium will be able to tap into the data, technology, analytics, and other resources they need to commercialize with speed, agility, and scale. We look forward to supporting Corium and bringing this valuable medicine to market for patients and families managing ADHD.”

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 72,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Tor Constantino, IQVIA Media Relations ([email protected])

+1.484.567.6732

Nick Childs, IQVIA Investor Relations ([email protected])

+1.973.316.3828

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Data Management Health Technology Software Pharmaceutical Biotechnology

MEDIA:

CCL Industries Expands in Singapore

TORONTO, May 03, 2021 (GLOBE NEWSWIRE) — CCL Industries Inc., a world leader in specialty label, security and packaging solutions for global corporations, government institutions, small businesses and consumers, announced today it has acquired privately held Lux Global Label Asia Pte. Ltd. (“LUX”), based in Singapore. LUX produces decorative labels for global consumer customers in the ASEAN region. For the trailing twelve months ending March 31, 2021, sales were $9.2 million, with adjusted EBITDA of approximately $1.0 million. The estimated $9.4 million purchase price is expected to equate approximately to the fair market value of the tangible fixed assets (including an owned building in Singapore) and working capital acquired. LUX will immediately move to trade as CCL Label Singapore.

Geoffrey T. Martin, President and Chief Executive Officer, of CCL Industries Inc., commented, “We are pleased to expand our highly successful operations in Asia and welcome LUX employees to CCL. We expect to improve the financial and operational performance of the acquired business significantly.”


Forward-looking Statements

This press release contains forward-looking information and forward-looking statements (hereinafter collectively referred to as “forward-looking statements”), as defined under applicable securities laws, that involve a number of risks and uncertainties. Forward-looking statements include all statements that are predictive in nature or depend on future events or conditions. Forward-looking statements are typically identified by the words “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions. Statements regarding the operations, business, financial condition, priorities, ongoing objectives, strategies and outlook of the Company, other than statements of historical fact, are forward-looking statements. Specifically, this press release contains forward-looking statements regarding CCL’s effect on the financial and operational performance of the acquired business.

Forward-looking statements are not guarantees of future performance. They involve known and unknown risks and uncertainties relating to future events and conditions including, but not limited to, the impact of competition; consumer confidence and spending preferences; general economic and geopolitical conditions; currency exchange rates; interest rates and credit availability; technological change; changes in government regulations; risks associated with operating and product hazards; and the Company’s ability to attract and retain qualified employees. Do not unduly rely on forward-looking statements as the Company’s actual results could differ materially from those anticipated in these forward-looking statements. Forward-looking statements are also based on a number of assumptions, which may prove to be incorrect, including, but not limited to, assumptions about the following: global economic environment and higher consumer spending; improved customer demand for the Company’s products; continued historical growth trends, market growth in specific sectors and entering into new sectors; the Company’s ability to provide a wide range of products to multinational customers on a global basis; the benefits of the Company’s focused strategies and operational approach; the achievement of the Company’s plans for improved efficiency and lower costs, including stable aluminum costs; the availability of cash and credit; fluctuations of currency exchange rates; fluctuations in resin prices; the Company’s continued relations with its customers; the Company’s estimated annual cost reductions and financial impact from the restructuring of the Checkpoint and Innovia acquisitions; and economic conditions. Should one or more risks materialize or should any assumptions prove incorrect, then actual results could vary materially from those expressed or implied in the forward-looking statements. Further details on key risks can be found in the Management’s Discussion and Analysis section of the 2020 Annual Report, particularly under Section 4: “Risks and Uncertainties.” CCL Industries Inc.’s annual and quarterly reports can be found online at www.cclind.com and www.sedar.com or are available upon request.

Except as otherwise indicated, forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made may have on the Company’s business. Such statements do not, unless otherwise specified by the Company, reflect the impact of dispositions, sales of assets, monetizations, mergers, acquisitions, other business combinations or transactions, asset write-downs or other charges announced or occurring after forward-looking statements are made. The financial impact of these transactions and non-recurring and other special items can be complex and depends on the facts particular to each of them and therefore cannot be described in a meaningful way in advance of knowing specific facts. The forward-looking statements are provided as of the date of this press release and the Company does not assume any obligation to update or revise the forward-looking statements to reflect new events or circumstances, except as required by law.

The financial information presented herein is expressed in Canadian dollars unless otherwise stated.

For more information on CCL, visit – www.cclind.com or contact:
     
Sean Washchuk

Senior Vice President 
and Chief Financial Officer
416-756-8526


CCL Industries Inc. employs approximately 22,200 people operating 191 production facilities in 42 countries with corporate offices in Toronto, Canada, and Framingham, Massachusetts. CCL is the world’s largest converter of pressure sensitive and specialty extruded film materials for a wide range of decorative, instructional, functional and security applications for government institutions and large global customers in the consumer packaging, healthcare & chemicals, consumer electronic device and automotive markets. Extruded & laminated plastic tubes, aluminum aerosols & specialty bottles, folded instructional leaflets, precision decorated & die cut components, electronic displays, polymer banknote substrate and other complementary products and services are sold in parallel to specific end-use markets. Avery is the world’s largest supplier of labels, specialty converted media and software solutions for short-run digital printing applications for businesses and consumers available alongside complementary products sold through distributors, mass market stores and e-commerce retailers. Checkpoint is a leading developer of RF and RFID based technology systems for loss prevention and inventory management applications, including labeling and tagging solutions, for the retail and apparel industries worldwide. Innovia is a leading global producer of specialty, high performance, multi-layer, surface engineered films for label, packaging and security applications. The Company is partly backward integrated into materials science with capabilities in polymer extrusion, adhesive development, coating & lamination, surface engineering and metallurgy; deployed as needed across the four business segments.